<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04317924</url>
  </required_header>
  <id_info>
    <org_study_id>H-37652</org_study_id>
    <nct_id>NCT04317924</nct_id>
  </id_info>
  <brief_title>Pneumostasis With Use of Bio-absorbable Mesh and Fibrin Sealant in Lung Resection</brief_title>
  <official_title>Use of Polyglycolic Acid Felt for Air-leak Prevention After Lung Resection</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boston Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Gunze Limited</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Boston Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Prolonged air leak, defined as air leak present 5 days after lung resection, is one of the
      most common complications after lung resection. This leads to patient discomfort (as the
      chest tube has to stay in place while air leak is present), prolonged stay, and increased
      cost.

      NeoVeil is a bioabsorbable glycolic acid which has been used in Japan and other Asian
      countries for air leak prevention after lung resections. NeoVeil is impregnated with fibrin
      sealant materials and is placed on the lung surface at the time of operation. It then acts as
      a scaffold on resected area which is prone to air leak.

      This randomized clinical trial will be the first in the United States to test its efficacy
      for air leak prevention.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">August 2020</start_date>
  <completion_date type="Anticipated">June 2022</completion_date>
  <primary_completion_date type="Anticipated">June 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Stratified block randomization will be done using known predictors of prolonged air leak: 1) surgical procedure (wedge vs lobectomy) and 2) presence of pulmonary comorbidities (chronic obstructive pulmonary disease and emphysema).</intervention_model_description>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Time to removal of chest tubes</measure>
    <time_frame>2 years</time_frame>
    <description>The time in hours to removal of chest tubes post lung resection will be abstracted from the electronic medical record of each participant.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Length of hospital stay</measure>
    <time_frame>2 years</time_frame>
    <description>The length of hospital stay in days will be abstracted from the electronic medical record of each participant.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with additional interventions for air leak</measure>
    <time_frame>2 years</time_frame>
    <description>The number of participants requiring additional interventions post lung resection will be abstracted from the electronic medical record of each participant.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Air Leak From Lung</condition>
  <arm_group>
    <arm_group_label>Reinforcement of air leak</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants in this arm will receive reinforcement with the NEOVEIL (polyglycolic acid felt) which will be impregnated with human fibrinogen and thrombin.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>No reinforcement of air leak</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants in this arm will receive standard of care for air leak post lung resection.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Polyglycolic acid felt</intervention_name>
    <description>Neoveil is a polyglycolic acid felt that has been shown to decrease the incidence of prolonged air leak after lung resection in Japan.</description>
    <arm_group_label>Reinforcement of air leak</arm_group_label>
    <other_name>Neoveil</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Standard of care</intervention_name>
    <description>Standard of care after air leak post lung resection</description>
    <arm_group_label>No reinforcement of air leak</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients undergoing elective lung resection at BMC

          -  Intra-operative diagnosis of air leak

        Exclusion Criteria:

          -  Patients undergoing emergency lung resection
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kei Suzuki, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Boston Medical Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Kei Suzuki, MD</last_name>
    <phone>(617)638-7377</phone>
    <email>kei.suzuki@bmc.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Ogheneyoma Akpoviroro, MD</last_name>
    <phone>617 414 6832</phone>
    <email>Ogheneyoma.Akpoviroro@bmc.org</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Boston Medical Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02118</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Kei Suzuki, MD</last_name>
      <phone>617-638-7377</phone>
      <email>kei.suzuki@bmc.org</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>March 20, 2020</study_first_submitted>
  <study_first_submitted_qc>March 20, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">March 23, 2020</study_first_posted>
  <last_update_submitted>May 25, 2020</last_update_submitted>
  <last_update_submitted_qc>May 25, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 27, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Pneumostasis</keyword>
  <keyword>Bio-absorbable mesh</keyword>
  <keyword>Lung resection</keyword>
  <keyword>Neoveil</keyword>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

